Literature DB >> 33395481

Molecular classification and deconvolution of the immune microenvironment in glioblastoma.

Matija Snuderl1.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33395481      PMCID: PMC7906051          DOI: 10.1093/neuonc/noaa291

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.

Authors:  Emmanuelle di Tomaso; Matija Snuderl; Walid S Kamoun; Dan G Duda; Pavan K Auluck; Ladan Fazlollahi; Ovidiu C Andronesi; Matthew P Frosch; Patrick Y Wen; Scott R Plotkin; E Tessa Hedley-Whyte; A Gregory Sorensen; Tracy T Batchelor; Rakesh K Jain
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

2.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Authors:  Qianghu Wang; Baoli Hu; Xin Hu; Hoon Kim; Massimo Squatrito; Lisa Scarpace; Ana C deCarvalho; Sali Lyu; Pengping Li; Yan Li; Floris Barthel; Hee Jin Cho; Yu-Hsi Lin; Nikunj Satani; Emmanuel Martinez-Ledesma; Siyuan Zheng; Edward Chang; Charles-Etienne Gabriel Sauvé; Adriana Olar; Zheng D Lan; Gaetano Finocchiaro; Joanna J Phillips; Mitchel S Berger; Konrad R Gabrusiewicz; Guocan Wang; Eskil Eskilsson; Jian Hu; Tom Mikkelsen; Ronald A DePinho; Florian Muller; Amy B Heimberger; Erik P Sulman; Do-Hyun Nam; Roel G W Verhaak
Journal:  Cancer Cell       Date:  2017-07-10       Impact factor: 31.743

Review 3.  The role of microglia and macrophages in glioma maintenance and progression.

Authors:  Dolores Hambardzumyan; David H Gutmann; Helmut Kettenmann
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

4.  DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival.

Authors:  Joost Dejaegher; Lien Solie; Zoé Hunin; Raf Sciot; David Capper; Christin Siewert; Sofie Van Cauter; Guido Wilms; Johan van Loon; Nadine Ectors; Steffen Fieuws; Stefan M Pfister; Stefaan W Van Gool; Steven De Vleeschouwer
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

5.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

7.  Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors.

Authors:  Ioannis Kaffes; Frank Szulzewsky; Zhihong Chen; Cameron J Herting; Ben Gabanic; José E Velázquez Vega; Jennifer Shelton; Jeffrey M Switchenko; James L Ross; Leon F McSwain; Jason T Huse; Bengt Westermark; Sven Nelander; Karin Forsberg-Nilsson; Lene Uhrbom; Naga Prathyusha Maturi; Patrick J Cimino; Eric C Holland; Helmut Kettenmann; Cameron W Brennan; Daniel J Brat; Dolores Hambardzumyan
Journal:  Oncoimmunology       Date:  2019-08-22       Impact factor: 8.110

8.  Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.

Authors:  Xin Cui; Chao Ma; Varshini Vasudevaraja; Jonathan Serrano; Jie Tong; Yansong Peng; Michael Delorenzo; Guomiao Shen; Joshua Frenster; Renee-Tyler Tan Morales; Weiyi Qian; Aristotelis Tsirigos; Andrew S Chi; Rajan Jain; Sylvia C Kurz; Erik P Sulman; Dimitris G Placantonakis; Matija Snuderl; Weiqiang Chen
Journal:  Elife       Date:  2020-09-10       Impact factor: 8.140

9.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

Authors:  David A Reardon; Alba A Brandes; Antonio Omuro; Paul Mulholland; Michael Lim; Antje Wick; Joachim Baehring; Manmeet S Ahluwalia; Patrick Roth; Oliver Bähr; Surasak Phuphanich; Juan Manuel Sepulveda; Paul De Souza; Solmaz Sahebjam; Michael Carleton; Kay Tatsuoka; Corina Taitt; Ricardo Zwirtes; John Sampson; Michael Weller
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.